MINT: Medically Intensive Nutrition Therapy Program for Obesity and Diabetes in a Low-income Population

Sponsor
Massachusetts General Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05799222
Collaborator
(none)
20
1
15.6
1.3

Study Details

Study Description

Brief Summary

This study is being done to better understand whether meal replacements can be an effective tool for weight loss and treatment of elevated blood sugars in people with obesity/overweight and diabetes/pre-diabetes who have a low income.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Bariatrix Meal Replacement Products

Detailed Description

The Medically Intensive Nutritional Therapy (MINT) program at Massachusetts General Hospital (MGH) Weight Center is a low-calorie nutrition plan that may offer a solution for those who have difficulty implementing a low-calorie dietary plan on their own. This study examines the effects of MINT on weight loss and blood sugar control specifically in a low-income population and explores potential reasons for discontinuing the program.

Study Design

Study Type:
Observational
Anticipated Enrollment :
20 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Feasibility Study of an Intensive Nutrition Therapy Program for Improvement of Obesity and Diabetes in a Low-income Population
Anticipated Study Start Date :
Apr 1, 2023
Anticipated Primary Completion Date :
Jul 18, 2024
Anticipated Study Completion Date :
Jul 18, 2024

Arms and Interventions

Arm Intervention/Treatment
Adults with overweight/obesity and pre-diabetes/diabetes and low income

Adults with overweight or obesity and pre-diabetes or type 2 diabetes who earn a low income.

Dietary Supplement: Bariatrix Meal Replacement Products
Meal replacement products offered through the Massachusetts General Hospital Weight Center.

Outcome Measures

Primary Outcome Measures

  1. Body weight reduction [3 months]

    Reduction in body weight by greater than or equal to 5 percent

  2. Hemoglobin A1c reduction [3 months]

    Reduction of Hemoglobin A1c by greater than or equal to 0.5 percent

Secondary Outcome Measures

  1. Program adherence [3 months]

    Adherence with the program, and potential reasons for non-adherence as assessed with bi-weekly questionnaires

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 18-65

  • Body mass index (BMI) greater than or equal to 27 kg/m^2

  • HgA1C greater than or equal to 5.7 percent or fasting glucose greater than or equal to 100mg/dL within the previous 6 months

  • Low-income as defined by having a family income at or below 400 percent of the federal poverty level guidelines for 2022

Exclusion Criteria:
  • Current use of antihyperglycemic agents (other than metformin) or approved anti- obesity medications or plans to start such regimens over the 3 months post-study enrollment

  • HbA1c greater than or equal to 10 percent

  • Plans to pursue bariatric surgery over the 6 months post-study enrollment

  • Weight loss of greater than 5 kg within the previous 3 months

  • Current active eating disorder, with the exception of binge eating disorder

  • Severe active psychiatric disease or significant cognitive impairment deemed by investigator likely to impede adherence to piloted intervention

  • Active illicit substance abuse

  • Pregnant, breastfeeding, or considering pregnancy within the next 6 months

  • Current participation in another clinical research trial deemed by investigator to conflict with current study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Massachusetts General Hospital Boston Massachusetts United States 02114

Sponsors and Collaborators

  • Massachusetts General Hospital

Investigators

  • Principal Investigator: Chika V Anekwe, MD, Mass General Brigham

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Chika V. Anekwe, MD, MPH, Instructor in Medicine, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT05799222
Other Study ID Numbers:
  • 2022P001451
First Posted:
Apr 5, 2023
Last Update Posted:
Apr 5, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 5, 2023